Aggiornamento aziendale8 ott 2026ENPhase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetPharvaris N.V.Company newsroom
Aggiornamento aziendale5 ott 2026ENReal-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyPharvaris N.V.Company newsroom
Aggiornamento aziendale8 set 2026ENPharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE AttacksPharvaris N.V.Company newsroom
Aggiornamento aziendale3 set 2026ENPharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026Pharvaris N.V.Company newsroom
Aggiornamento aziendale12 ago 2026ENPharvaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatePharvaris N.V.Company newsroom
Aggiornamento aziendale6 ago 2026ENAssessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in ImmunologyPharvaris N.V.Company newsroom
Aggiornamento aziendale22 lug 2026ENPublication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated AngioedemaPharvaris N.V.Company newsroom
Aggiornamento aziendale6 lug 2026ENPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema AttacksPharvaris N.V.Company newsroom
Aggiornamento aziendale15 giu 2026ENData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026Pharvaris N.V.Company newsroom
Aggiornamento aziendale11 giu 2026ENPharvaris Announces Annual General Meeting of ShareholdersPharvaris N.V.Company newsroom
Aggiornamento aziendale29 mag 2026ENPharvaris to Present Clinical Data at the EAACI Annual Congress 2026Pharvaris N.V.Company newsroom
Aggiornamento aziendale12 mag 2026ENPharvaris Reports First Quarter 2026 Financial Results and Provides Business UpdatePharvaris N.V.Company newsroom
